This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Soignet, S. L. Articles by Warrell, R. P. Search for Related Content PubMed PubMed Citation Articles by Soignet, S. L. Articles by Warrell, R. P., Jr Social Bookmarking                            What's this?

United States Multicenter Study of Arsenic Trioxide in Relapsed Acute Promyelocytic Leukemia

From the Leukemia and Developmental Chemotherapy Services, Department of Medicine, and Pediatric Department, Memorial Sloan-Kettering Cancer Center and Joan and Sanford Weill Medical College of Cornell University, New York, NY; Lombardi Cancer Center, Georgetown University Medical Center, Washington, DC; Norris Cancer Center and University of Southern California Keck School of Medicine, University of Southern California, Los Angeles; Stanford University Medical Center, Stanford, CA; Northwestern University of Medical School, Chicago, IL; M.D. Anderson Cancer Center, Houston, TX; Dana-Farber Cancer Center, Boston, MA; Cleveland Clinic Foundation, Cleveland, OH; and Fred Hutchinson Cancer Research Center and Cell Therapeutics Inc, Seattle, WA.

Address reprint requests to Steven L. Soignet, MD, Memorial Sloan-Kettering Cancer Center, 1275 York Ave, New York, NY 10021; email: soignets{at}mskcc.org

PURPOSE: To determine the safety and efficacy of arsenic trioxide (ATO) in patients with relapsed acute promyelocytic leukemia (APL).

PATIENTS AND METHODS: Forty patients experiencing first (n = 21) or second (n = 19) relapse were treated with daily infusions of ATO to a maximum of 60 doses or until all leukemic cells in bone marrow were eliminated. Patients who achieved a complete remission (CR) were offered one consolidation course of ATO that began 3 to 4 weeks later. Patients who remained in CR were eligible to receive further cycles of ATO therapy on a maintenance study.

RESULTS: Thirty-four patients (85%) achieved a CR. Thirty-one patients (91%) with CRs had posttreatment cytogenetic tests negative for t(15;17). Eighty-six percent of the patients who were assessable by reverse transcriptase polymerase chain reaction converted from positive to negative for the promyelocytic leukemia/retinoic acid receptor-alpha transcript by the completion of their consolidation therapy. Thirty-two patients received consolidation therapy, and 18 received additional ATO as maintenance. Eleven patients underwent allogeneic (n = 8) or autologous (n = 3) transplant after ATO treatment. The 18-month overall and relapse-free survival (RFS) estimates were 66% and 56%, respectively. Twenty patients (50%) had leukocytosis (> 10,000 WBC/µL) during induction therapy. Ten patients developed signs or symptoms suggestive of the APL syndrome and were effectively treated with dexamethasone. Electrocardiographic QT prolongation was common (63%). One patient had an absolute QT interval of > 500 msec and had an asymptomatic 7-beat run of torsades de pointe. Two patients died during induction, neither from drug-related causes.

CONCLUSION: This study establishes ATO as a highly effective therapy for patients with relapsed APL.

S.L.S. is a Mortimer J. Lacher fellow.

Presented in part at the Annual Meeting of the American Society of Hematology, San Francisco, CA, December 1-5, 2000.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				E. T.H. Yeh and C. L. Bickford Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. J. Am. Coll. Cardiol., June 16, 2009; 53(24): 2231 - 2247. [Abstract] [Full Text] [PDF]

				D. Nowak, D. Stewart, and H. P. Koeffler Differentiation therapy of leukemia: 3 decades of development Blood, April 16, 2009; 113(16): 3655 - 3665. [Abstract] [Full Text] [PDF]

				M. A. Sanz, D. Grimwade, M. S. Tallman, B. Lowenberg, P. Fenaux, E. H. Estey, T. Naoe, E. Lengfelder, T. Buchner, H. Dohner, et al. Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet Blood, February 26, 2009; 113(9): 1875 - 1891. [Abstract] [Full Text] [PDF]

				F. Ravandi, E. Estey, D. Jones, S. Faderl, S. O'Brien, J. Fiorentino, S. Pierce, D. Blamble, Z. Estrov, W. Wierda, et al. Effective Treatment of Acute Promyelocytic Leukemia With All-Trans-Retinoic Acid, Arsenic Trioxide, and Gemtuzumab Ozogamicin J. Clin. Oncol., February 1, 2009; 27(4): 504 - 510. [Abstract] [Full Text] [PDF]

				Y. MOLIN, P. FRISK, and N.-G. ILBACK Arsenic Trioxide Affects the Trace Element Balance in Tissues in Infected and Healthy Mice Differently Anticancer Res, January 1, 2009; 29(1): 83 - 90. [Abstract] [Full Text] [PDF]

				H. M. Pettersson, A. Pietras, M. Munksgaard Persson, J. Karlsson, L. Johansson, M. C. Shoshan, and S. Pahlman Arsenic trioxide is highly cytotoxic to small cell lung carcinoma cells Mol. Cancer Ther., January 1, 2009; 8(1): 160 - 170. [Abstract] [Full Text] [PDF]

				V. L. Bae-Jump, Chunxiao Zhou, J. F. Boggess, and P. A. Gehrig Arsenic Trioxide (As2O3) Inhibits Expression of Estrogen Receptor--alpha Through Regulation of the Mitogen-activated Protein Kinase (MAPK) Pathway in Endometrial Cancer Cells Reproductive Sciences, December 1, 2008; 15(10): 1011 - 1017. [Abstract] [PDF]

				A. Yoda, K. Toyoshima, Y. Watanabe, N. Onishi, Y. Hazaka, Y. Tsukuda, J. Tsukada, T. Kondo, Y. Tanaka, and Y. Minami Arsenic Trioxide Augments Chk2/p53-mediated Apoptosis by Inhibiting Oncogenic Wip1 Phosphatase J. Biol. Chem., July 4, 2008; 283(27): 18969 - 18979. [Abstract] [Full Text] [PDF]

				R. Cashin, L. Burry, K. Peckham, S. Reynolds, and J. T. Seki Acute renal failure, gastrointestinal bleeding, and cardiac arrhythmia after administration of arsenic trioxide for acute promyelocytic leukemia Am. J. Health Syst. Pharm., May 15, 2008; 65(10): 941 - 946. [Abstract] [Full Text] [PDF]

				B. Dolniak, E. Katsoulidis, N. Carayol, J. K. Altman, A. J. Redig, M. S. Tallman, T. Ueda, R. Watanabe-Fukunaga, R. Fukunaga, and L. C. Platanias Regulation of Arsenic Trioxide-induced Cellular Responses by Mnk1 and Mnk2 J. Biol. Chem., May 2, 2008; 283(18): 12034 - 12042. [Abstract] [Full Text] [PDF]

				B. L. Frei and S. A. Soefje A Review of the Cardiovascular Effects of Oncology Agents Journal of Pharmacy Practice, April 1, 2008; 21(2): 146 - 158. [Abstract] [PDF]

				Z.-Y. Wang and Z. Chen Acute promyelocytic leukemia: from highly fatal to highly curable Blood, March 1, 2008; 111(5): 2505 - 2515. [Abstract] [Full Text] [PDF]

				J. K. Altman, P. Yoon, E. Katsoulidis, B. Kroczynska, A. Sassano, A. J. Redig, H. Glaser, A. Jordan, M. S. Tallman, N. Hay, et al. Regulatory Effects of Mammalian Target of Rapamycin-mediated Signals in the Generation of Arsenic Trioxide Responses J. Biol. Chem., January 25, 2008; 283(4): 1992 - 2001. [Abstract] [Full Text] [PDF]

				E. Fox, B. I. Razzouk, B. C. Widemann, S. Xiao, M. O'Brien, W. Goodspeed, G. H. Reaman, S. M. Blaney, A. J. Murgo, F. M. Balis, et al. Phase 1 trial and pharmacokinetic study of arsenic trioxide in children and adolescents with refractory or relapsed acute leukemia, including acute promyelocytic leukemia or lymphoma Blood, January 15, 2008; 111(2): 566 - 573. [Abstract] [Full Text] [PDF]

				M. S. Tallman and J. K. Altman Curative Strategies in Acute Promyelocytic Leukemia Hematology, January 1, 2008; 2008(1): 391 - 399. [Abstract] [Full Text] [PDF]

				H. Fung, P. Liu, and B. Demple ATF4-Dependent Oxidative Induction of the DNA Repair Enzyme Ape1 Counteracts Arsenite Cytotoxicity and Suppresses Arsenite-Mediated Mutagenesis Mol. Cell. Biol., December 15, 2007; 27(24): 8834 - 8847. [Abstract] [Full Text] [PDF]

				G. Cunha De Santis, M. de Barros Tamarozzi, R. B. Sousa, S. E. Moreno, D. Secco, A. B. Garcia, A. S. G. Lima, L. H. Faccioli, R. P. Falcao, F. Q. Cunha, et al. Adhesion molecules and differentiation syndrome: phenotypic and functional analysis of the effect of ATRA, As2O3, phenylbutyrate, and G-CSF in acute promyelocytic leukemia Haematologica, December 1, 2007; 92(12): 1615 - 1622. [Abstract] [Full Text] [PDF]

				A. Catalano, M. A. Dawson, K. Somana, S. Opat, A. Schwarer, L. J. Campbell, and H. Iland The PRKAR1A gene is fused to RARA in a new variant acute promyelocytic leukemia Blood, December 1, 2007; 110(12): 4073 - 4076. [Abstract] [Full Text] [PDF]

				M. Vujcic, M. Shroff, and K. K. Singh Genetic Determinants of Mitochondrial Response to Arsenic in Yeast Saccharomyces cerevisiae Cancer Res., October 15, 2007; 67(20): 9740 - 9749. [Abstract] [Full Text] [PDF]

				B. C. Bornhauser, L. Bonapace, D. Lindholm, R. Martinez, G. Cario, M. Schrappe, F. K. Niggli, B. W. Schafer, and J.-P. Bourquin Low-dose arsenic trioxide sensitizes glucocorticoid-resistant acute lymphoblastic leukemia cells to dexamethasone via an Akt-dependent pathway Blood, September 15, 2007; 110(6): 2084 - 2091. [Abstract] [Full Text] [PDF]

				G.-B. Zhou, J. Zhang, Z.-Y. Wang, S.-J. Chen, and Z. Chen Treatment of acute promyelocytic leukaemia with all-trans retinoic acid and arsenic trioxide: a paradigm of synergistic molecular targeting therapy Phil Trans R Soc B, June 29, 2007; 362(1482): 959 - 971. [Abstract] [Full Text] [PDF]

				F. Braiteh and R. Kurzrock Uncommon tumors and exceptional therapies: paradox or paradigm? Mol. Cancer Ther., April 1, 2007; 6(4): 1175 - 1179. [Abstract] [Full Text] [PDF]

				F. Lo-Coco, E. Ammatuna, and M. A. Sanz Current treatment of acute promyelocytic leukemia Haematologica, March 1, 2007; 92(3): 289 - 291. [Full Text] [PDF]

				S. Kitareewan, B. D. Roebuck, E. Demidenko, R. D. Sloboda, and E. Dmitrovsky Lysosomes and Trivalent Arsenic Treatment in Acute Promyelocytic Leukemia J Natl Cancer Inst, January 3, 2007; 99(1): 41 - 52. [Abstract] [Full Text] [PDF]

				H. C. Kwaan Double Hazard of Thrombophilia and Bleeding in Leukemia Hematology, January 1, 2007; 2007(1): 151 - 157. [Abstract] [Full Text] [PDF]

				T. A. Zykova, F. Zhu, C. Lu, L. Higgins, Y. Tatsumi, Y. Abe, A. M. Bode, and Z. Dong Lymphokine-Activated Killer T-Cell-Originated Protein Kinase Phosphorylation of Histone H2AX Prevents Arsenite-Induced Apoptosis in RPMI7951 Melanoma Cells Clin. Cancer Res., December 1, 2006; 12(23): 6884 - 6893. [Abstract] [Full Text] [PDF]

				W. Yang, J. Ge, H. Liu, K. Zhao, X. Liu, X. Qu, W. Li, Y. Huang, A. Sun, and Y. Zou Arsenic trioxide eluting stent reduces neointima formation in a rabbit iliac artery injury model Cardiovasc Res, December 1, 2006; 72(3): 483 - 493. [Abstract] [Full Text] [PDF]

				A Vahidnia, F Romijn, M Tiller, G B van der Voet, and F A de Wolff Arsenic-induced toxicity: effect on protein composition in sciatic nerve Human and Experimental Toxicology, November 1, 2006; 25(11): 667 - 674. [Abstract] [PDF]

				S. Ghaffari, S Rostami, D Bashash, K Alimoghaddam, and A Ghavamzadeh Real-time PCR analysis of PML-RAR{alpha} in newly diagnosed acute promyelocytic leukaemia patients treated with arsenic trioxide as a front-line therapy Ann. Onc., October 1, 2006; 17(10): 1553 - 1559. [Abstract] [Full Text] [PDF]

				P. Kannan-Thulasiraman, E. Katsoulidis, M. S. Tallman, J. S. C. Arthur, and L. C. Platanias Activation of the Mitogen- and Stress-activated Kinase 1 by Arsenic Trioxide J. Biol. Chem., August 11, 2006; 281(32): 22446 - 22452. [Abstract] [Full Text] [PDF]

				C.-W. Siu, W.-Y. Au, C. Yung, C. R. Kumana, C.-P. Lau, Y.-L. Kwong, and H.-F. Tse Effects of oral arsenic trioxide therapy on QT intervals in patients with acute promyelocytic leukemia: implications for long-term cardiac safety Blood, July 1, 2006; 108(1): 103 - 106. [Abstract] [Full Text] [PDF]

				G. J. Schiller, J. Slack, J. D. Hainsworth, J. Mason, M. Saleh, D. Rizzieri, D. Douer, and A. F. List Phase II Multicenter Study of Arsenic Trioxide in Patients With Myelodysplastic Syndromes J. Clin. Oncol., June 1, 2006; 24(16): 2456 - 2464. [Abstract] [Full Text] [PDF]

				N. Vey, A. Bosly, A. Guerci, W. Feremans, H. Dombret, F. Dreyfus, D. Bowen, A. Burnett, M. Dennis, V. Ribrag, et al. Arsenic Trioxide in Patients With Myelodysplastic Syndromes: A Phase II Multicenter Study J. Clin. Oncol., June 1, 2006; 24(16): 2465 - 2471. [Abstract] [Full Text] [PDF]

				E. Estey, G. Garcia-Manero, A. Ferrajoli, S. Faderl, S. Verstovsek, D. Jones, and H. Kantarjian Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia Blood, May 1, 2006; 107(9): 3469 - 3473. [Abstract] [Full Text] [PDF]

				V. Mathews, B. George, K. M. Lakshmi, A. Viswabandya, A. Bajel, P. Balasubramanian, R. V. Shaji, V. M. Srivastava, A. Srivastava, and M. Chandy Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: durable remissions with minimal toxicity Blood, April 1, 2006; 107(7): 2627 - 2632. [Abstract] [Full Text] [PDF]

				E. J. Jabbour, E. Estey, and H. M. Kantarjian Adult Acute Myeloid Leukemia Mayo Clin. Proc., February 1, 2006; 81(2): 247 - 260. [Abstract] [Full Text] [PDF]

				A. Lemarie, C. Morzadec, D. Merino, O. Micheau, O. Fardel, and L. Vernhet Arsenic Trioxide Induces Apoptosis of Human Monocytes during Macrophagic Differentiation through Nuclear Factor-{kappa}B-Related Survival Pathway Down-Regulation J. Pharmacol. Exp. Ther., January 1, 2006; 316(1): 304 - 314. [Abstract] [Full Text] [PDF]

				A. Ghavamzadeh, K. Alimoghaddam, S. H. Ghaffari, S. Rostami, M. Jahani, R. Hosseini, A. Mossavi, E. Baybordi, A. Khodabadeh, M. Iravani, et al. Treatment of acute promyelocytic leukemia with arsenic trioxide without ATRA and/or chemotherapy Ann. Onc., January 1, 2006; 17(1): 131 - 134. [Abstract] [Full Text] [PDF]

				M. A. Sanz, M. S. Tallman, and F. Lo-Coco Practice Points, Consensus, and Controversial Issues in the Management of Patients with Newly Diagnosed Acute Promyelocytic Leukemia Oncologist, November 1, 2005; 10(10): 806 - 814. [Abstract] [Full Text] [PDF]

				J. D. Floyd, D. T. Nguyen, R. L. Lobins, Q. Bashir, D. C. Doll, and M. C. Perry Cardiotoxicity of Cancer Therapy J. Clin. Oncol., October 20, 2005; 23(30): 7685 - 7696. [Abstract] [Full Text] [PDF]

				J. Karlsson, A. Edsjo, S. Pahlman, and H. M. Pettersson Multidrug-resistant neuroblastoma cells are responsive to arsenic trioxide at both normoxia and hypoxia Mol. Cancer Ther., July 1, 2005; 4(7): 1128 - 1135. [Abstract] [Full Text] [PDF]

				N. Karasavvas, J. M. Carcamo, G. Stratis, and D. W. Golde Vitamin C protects HL60 and U266 cells from arsenic toxicity Blood, May 15, 2005; 105(10): 4004 - 4012. [Abstract] [Full Text] [PDF]

				M. A. Sanz, M. S. Tallman, and F. Lo-Coco Tricks of the trade for the appropriate management of newly diagnosed acute promyelocytic leukemia Blood, April 15, 2005; 105(8): 3019 - 3025. [Abstract] [Full Text] [PDF]

				D. Douer and M. S. Tallman Arsenic Trioxide: New Clinical Experience With an Old Medication in Hematologic Malignancies J. Clin. Oncol., April 1, 2005; 23(10): 2396 - 2410. [Abstract] [Full Text] [PDF]

				Z. Diaz, M. Colombo, K. K. Mann, H. Su, K. N. Smith, D. S. Bohle, H. M. Schipper, and W. H. Miller Jr Trolox selectively enhances arsenic-mediated oxidative stress and apoptosis in APL and other malignant cell lines Blood, February 1, 2005; 105(3): 1237 - 1245. [Abstract] [Full Text] [PDF]

				S. de Botton, A. Fawaz, S. Chevret, H. Dombret, X. Thomas, M. Sanz, A. Guerci, J. San Miguel, J. de la Serna, A.M. Stoppa, et al. Autologous and Allogeneic Stem-Cell Transplantation As Salvage Treatment of Acute Promyelocytic Leukemia Initially Treated With All-Trans-Retinoic Acid: A Retrospective Analysis of the European Acute Promyelocytic Leukemia Group J. Clin. Oncol., January 1, 2005; 23(1): 120 - 126. [Abstract] [Full Text] [PDF]

				D. Douer Acute promyelocytic leukemia: a target for preemptive strike? Blood, October 1, 2004; 104(7): 1913 - 1914. [Full Text] [PDF]

				P. Lunghi, A. Costanzo, M. Levrero, and A. Bonati Treatment with arsenic trioxide (ATO) and MEK1 inhibitor activates the p73-p53AIP1 apoptotic pathway in leukemia cells Blood, July 15, 2004; 104(2): 519 - 525. [Abstract] [Full Text] [PDF]

				E. Ficker, Y. A. Kuryshev, A. T. Dennis, C. Obejero-Paz, L. Wang, P. Hawryluk, B. A. Wible, and A. M. Brown Mechanisms of Arsenic-Induced Prolongation of Cardiac Repolarization Mol. Pharmacol., July 1, 2004; 66(1): 33 - 44. [Abstract] [Full Text] [PDF]

				S. de Botton, V. Coiteux, S. Chevret, C. Rayon, E. Vilmer, M. Sanz, J. de La Serna, N. Philippe, A. Baruchel, G. Leverger, et al. Outcome of Childhood Acute Promyelocytic Leukemia With All-Trans-Retinoic Acid and Chemotherapy J. Clin. Oncol., April 15, 2004; 22(8): 1404 - 1412. [Abstract] [Full Text] [PDF]

				W.-C. Chou, C. Jie, A. A. Kenedy, R. J. Jones, M. A. Trush, and C. V. Dang Role of NADPH oxidase in arsenic-induced reactive oxygen species formation and cytotoxicity in myeloid leukemia cells PNAS, March 30, 2004; 101(13): 4578 - 4583. [Abstract] [Full Text] [PDF]

				B. Drolet, C. Simard, and D. M. Roden Unusual Effects of a QT-Prolonging Drug, Arsenic Trioxide, on Cardiac Potassium Currents Circulation, January 6, 2004; 109(1): 26 - 29. [Abstract] [Full Text] [PDF]

				R. M. Stone, M. R. O'Donnell, and M. A. Sekeres Acute Myeloid Leukemia Hematology, January 1, 2004; 2004(1): 98 - 117. [Abstract] [Full Text] [PDF]

				R. Nimmanapalli, P. Bali, E. O'Bryan, L. Fuino, F. Guo, J. Wu, P. Houghton, and K. Bhalla Arsenic Trioxide Inhibits Translation of mRNA of bcr-abl, Resulting in Attenuation of Bcr-Abl Levels and Apoptosis of Human Leukemia Cells Cancer Res., November 15, 2003; 63(22): 7950 - 7958. [Abstract] [Full Text] [PDF]

				J. T. Barbey, J. C. Pezzullo, and S. L. Soignet Effect of Arsenic Trioxide on QT Interval in Patients With Advanced Malignancies J. Clin. Oncol., October 1, 2003; 21(19): 3609 - 3615. [Abstract] [Full Text] [PDF]

				W.-Y. Au, C. R. Kumana, M. Kou, R. Mak, G. C. F. Chan, C.-W. Lam, and Y.-L. Kwong Oral arsenic trioxide in the treatment of relapsed acute promyelocytic leukemia Blood, July 1, 2003; 102(1): 407 - 408. [Full Text] [PDF]

				E. Raffoux, P. Rousselot, J. Poupon, M.-T. Daniel, B. Cassinat, R. Delarue, A.-L. Taksin, D. Rea, A. Buzyn, A. Tibi, et al. Combined Treatment With Arsenic Trioxide and All-Trans-Retinoic Acid in Patients With Relapsed Acute Promyelocytic Leukemia J. Clin. Oncol., June 15, 2003; 21(12): 2326 - 2334. [Abstract] [Full Text] [PDF]

				S. Sturlan, M. Baumgartner, E. Roth, and T. Bachleitner-Hofmann Docosahexaenoic acid enhances arsenic trioxide-mediated apoptosis in arsenic trioxide-resistant HL-60 cells Blood, June 15, 2003; 101(12): 4990 - 4997. [Abstract] [Full Text] [PDF]

				W. Y. Au, A. K. W. Lie, C. S. Chim, R. Liang, S. K. Ma, C. H. Chan, Y. K. Mak, Y. T. Chen, C. C. So, Y. M. Yeung, et al. Arsenic trioxide in comparison with chemotherapy and bone marrow transplantation for the treatment of relapsed acute promyelocytic leukaemia Ann. Onc., May 1, 2003; 14(5): 752 - 757. [Abstract] [Full Text] [PDF]

				D. Douer, W. Hu, S. Giralt, M. Lill, and J. DiPersio Arsenic Trioxide (Trisenox(R)) Therapy for Acute Promyelocytic Leukemia in the Setting of Hematopoietic Stem Cell Transplantation Oncologist, April 1, 2003; 8(2): 132 - 140. [Abstract] [Full Text] [PDF]

				Z.-y. Wang Ham-Wasserman Lecture: Treatment of Acute Leukemia by Inducing Differentiation and Apoptosis Hematology, January 1, 2003; 2003(1): 1 - 13. [Abstract] [Full Text] [PDF]

				B. Lowenberg, J. D. Griffin, and M. S. Tallman Acute Myeloid Leukemia and Acute Promyelocytic Leukemia Hematology, January 1, 2003; 2003(1): 82 - 101. [Abstract] [Full Text] [PDF]

				M. S. Tallman, J. W. Andersen, C. A. Schiffer, F. R. Appelbaum, J. H. Feusner, W. G. Woods, A. Ogden, H. Weinstein, L. Shepherd, C. Willman, et al. All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol Blood, December 15, 2002; 100(13): 4298 - 4302. [Abstract] [Full Text] [PDF]

				N. J. Bahlis, J. McCafferty-Grad, I. Jordan-McMurry, J. Neil, I. Reis, M. Kharfan-Dabaja, J. Eckman, M. Goodman, H. F. Fernandez, L. H. Boise, et al. Feasibility and Correlates of Arsenic Trioxide Combined with Ascorbic Acid-mediated Depletion of Intracellular Glutathione for the Treatment of Relapsed/Refractory Multiple Myeloma Clin. Cancer Res., December 1, 2002; 8(12): 3658 - 3668. [Abstract] [Full Text] [PDF]

				C.-E. Chiang, H.-N. Luk, T.-M. Wang, and P. Y.-A. Ding Prolongation of cardiac repolarization by arsenic trioxide Blood, August 28, 2002; 100(6): 2249 - 2252. [Abstract] [Full Text] [PDF]

				Y. S. Lew, A. Kolozsvary, S. L. Brown, and J. H. Kim Synergistic Interaction with Arsenic Trioxide and Fractionated Radiation in Locally Advanced Murine Tumor Cancer Res., August 1, 2002; 62(15): 4202 - 4205. [Abstract] [Full Text] [PDF]

				W. H. Miller Jr., H. M. Schipper, J. S. Lee, J. Singer, and S. Waxman Mechanisms of Action of Arsenic Trioxide Cancer Res., July 15, 2002; 62(14): 3893 - 3903. [Abstract] [Full Text] [PDF]

				P. Westervelt, J. L. Pollock, K. M. Oldfather, M. J. Walter, M. K. Ma, A. Williams, J. F. DiPersio, and T. J. Ley Adaptive immunity cooperates with liposomal all-trans-retinoic acid (ATRA) to facilitate long-term molecular remissions in mice with acute promyelocytic leukemia PNAS, July 9, 2002; 99(14): 9468 - 9473. [Abstract] [Full Text] [PDF]

				S.-F. Yip, Y.-M. Yeung, and E.-Y.-K. Tsui Severe neurotoxicity following arsenic therapy for acute promyelocytic leukemia: potentiation by thiamine deficiency Blood, May 1, 2002; 99(9): 3481 - 3482. [Full Text] [PDF]

				J. L. Slack, S. Waxman, G. Tricot, M. S. Tallman, and C. D. Bloomfield Advances in the Management of Acute Promyelocytic Leukemia and Other Hematologic Malignancies with Arsenic Trioxide Oncologist, April 1, 2002; 7(90001): 1 - 13. [Abstract] [Full Text] [PDF]

				W. H. Miller Jr. Molecular Targets of Arsenic Trioxide in Malignant Cells Oncologist, April 1, 2002; 7(90001): 14 - 19. [Abstract] [Full Text] [PDF]

				M. A. Hussein Nontraditional Cytotoxic Therapies for Relapsed/Refractory Multiple Myeloma Oncologist, April 1, 2002; 7(90001): 20 - 29. [Abstract] [Full Text] [PDF]

				M. O'Dwyer Multifaceted Approach to the Treatment of Bcr-Abl-Positive Leukemias Oncologist, April 1, 2002; 7(90001): 30 - 38. [Abstract] [Full Text] [PDF]

				M. S. Tallman, C. Nabhan, J. H. Feusner, and J. M. Rowe Acute promyelocytic leukemia: evolving therapeutic strategies Blood, February 1, 2002; 99(3): 759 - 767. [Abstract] [Full Text] [PDF]

				F. J. Giles, A. Keating, A. H. Goldstone, I. Avivi, C. L. Willman, and H. M. Kantarjian Acute Myeloid Leukemia Hematology, January 1, 2002; 2002(1): 73 - 110. [Abstract] [Full Text]